Prometrium vs Hormonal IUD (Mirena/Kyleena): What to Do When One Fails

Why You Need a Progestogen Alongside Estrogen HRT

You cannot take systemic estrogen for menopausal symptoms without also protecting your uterine lining. Estrogen alone stimulates endometrial cell growth. Without opposition from a progestogen, the risk of endometrial hyperplasia and endometrial cancer climbs significantly. The PEPI trial (JAMA, 1995) showed that unopposed estrogen produced endometrial hyperplasia in 62% of women over three years, compared with under 1% in women using combined estrogen-progestogen therapy.

That single number shapes nearly every HRT prescribing decision you and your clinician will make.

If you have had a hysterectomy, you do not need a progestogen at all. This article is specifically for women who have a uterus and are using or considering systemic estrogen HRT.

The Two Progestogen Strategies

Your two main options for delivering the progestogen component are:

1. Systemic oral progesterone (Prometrium, micronized progesterone): absorbed from the gut, reaches the bloodstream, and acts throughout the body including the brain.
2. Levonorgestrel-releasing IUD (Mirena 52 mg, Kyleena 19.5 mg): delivers a synthetic progestogen (levonorgestrel) directly into the uterine cavity, keeping most of the drug local and blood levels very low.

These are not interchangeable in terms of how they feel, what they do systemically, and who they suit best.

What Is Prometrium and How Does It Work in HRT?

Prometrium is oral micronized progesterone, the bioidentical form of the progesterone your ovaries produced during your reproductive years. In HRT, it is used in two patterns:

• Cyclical (sequential) regimen: 200 mg nightly for 12 to 14 days per calendar month, combined with daily estrogen. This produces a withdrawal bleed and is common in perimenopause.
• Continuous combined regimen: 100 mg nightly every day, combined with daily estrogen. Most post-menopausal women aim for this no-bleed pattern.

Endometrial Protection Evidence

The PEPI trial remains the landmark dataset here. Women using oral micronized progesterone had endometrial hyperplasia rates similar to those using synthetic progestins (medroxyprogesterone acetate), and the micronized progesterone group had a more favorable lipid profile than the MPA group. That cardiovascular signal is one reason many clinicians prefer Prometrium over older synthetic progestins.

ACOG Practice Bulletin No. 141 on managing menopausal symptoms confirms that micronized progesterone is an acceptable progestogen for endometrial protection in women using systemic estrogen.

The Systemic Side-Effect Reality

Because Prometrium is swallowed and absorbed systemically, it acts on progesterone receptors in the brain. That produces real effects:

• Sedation and drowsiness (the most common complaint, which is why evening dosing is standard)
• Low mood, tearfulness, or PMS-like symptoms in progesterone-sensitive women
• Breast tenderness
• Bloating

For some women these effects are mild or even welcome (the sedation aids sleep). For others, they are intolerable. Progesterone sensitivity is real, and women with a history of severe PMS or PMDD are more likely to notice systemic progesterone side effects from oral Prometrium.

Who Tends to Do Well on Prometrium

• Post-menopausal women with low progesterone sensitivity who want a simple oral regimen
• Women who welcome mild sedation at night
• Women whose clinician wants to preserve the cardiovascular benefit seen in the PEPI lipid data
• Women who prefer a bioidentical molecule

What Is the Levonorgestrel IUD and How Does It Work in HRT?

The levonorgestrel IUD (brand names Mirena at 52 mg and Kyleena at 19.5 mg) releases a synthetic progestogen directly into the uterine cavity. Mirena releases approximately 20 mcg of levonorgestrel per day initially, declining to around 10 mcg/day by five years. Kyleena releases about 17.5 mcg/day initially, declining over five years.

Local Action, Low Systemic Levels

Blood levels of levonorgestrel from the IUD are roughly 10-fold lower than those from oral contraceptive pills. That localized delivery is why many women who cannot tolerate systemic progestogen side effects from Prometrium find the IUD approach far more comfortable.

The NEJM 2013 trial comparing LNG-IUS to endometrial ablation for heavy menstrual bleeding enrolled 571 women and found that the levonorgestrel IUD was non-inferior to surgery for quality-of-life outcomes at two years, with 77% of IUD users reporting satisfaction versus 73% in the ablation group. While that trial was not an HRT study, it established the IUD's effectiveness at suppressing endometrial proliferation, the same mechanism that matters in HRT.

Off-Label Status in the United States

Mirena and Kyleena are FDA-approved for contraception and heavy menstrual bleeding, but their use as the progestogen component of HRT is off-label in the United States. This does not mean it is unsafe or unsupported. The British Menopause Society and many European prescribers consider it standard practice. The Menopause Society (formerly NAMS) 2022 Hormone Therapy Position Statement acknowledges the use of the LNG-IUD as a progestogen delivery method for HRT, while noting the off-label status. Being clear about that with your provider matters before you proceed.

Who Tends to Do Well on the LNG-IUD

• Women who cannot tolerate systemic progesterone side effects (mood changes, sedation, breast tenderness)
• Women in perimenopause who also need contraception (Mirena is a highly effective contraceptive)
• Women who want to reduce or eliminate withdrawal bleeds over time
• Women with fibroids or a history of heavy menstrual bleeding who are entering perimenopause on high-dose estrogen

Head-to-Head: Prometrium vs Levonorgestrel IUD

| Feature | Prometrium 100-200 mg oral | Mirena/Kyleena LNG-IUD | |---|---|---| | Route | Oral, systemic | Intrauterine, mostly local | | Molecule | Bioidentical progesterone | Levonorgestrel (synthetic) | | Endometrial protection | Well-established (PEPI, ACOG) | Effective; off-label in US HRT context | | Systemic side effects | Yes (sedation, mood, bloating) | Minimal | | Contraception | No | Yes (Mirena: >99% effective) | | Bleeding pattern | Cyclical withdrawal or no-bleed | Spotting initially; often amenorrhea | | Insertion procedure | None | Required; can be uncomfortable | | Duration | Daily pill | 5-8 years (Mirena), 5 years (Kyleena) | | Cost (approximate US) | $60-130/month without insurance | $800-1,300 device; often covered | | FDA-approved for HRT | Yes (with estrogen) | Off-label |

When Prometrium "Fails": What That Looks Like and What to Do

"Failure" in this context does not always mean the drug stopped protecting your endometrium. It usually means one of three things.

Intolerable Side Effects

If you are waking up groggy, feeling tearful in the two weeks you take the cyclical dose, or noticing breast pain that disrupts daily life, those are progesterone-sensitivity signals. Your first step is to confirm the dose is correct. The standard continuous dose is 100 mg nightly, not 200 mg. Some women are prescribed 200 mg nightly continuously, which exceeds standard guidance for the continuous regimen and can amplify side effects.

If the dose is correct and side effects persist for more than two to three months, switching to the LNG-IUD is a well-supported clinical move. The low systemic levonorgestrel levels from the IUD are far less likely to cause the mood and sedation effects you are experiencing.

Breakthrough Bleeding That Won't Resolve

Some breakthrough bleeding in the first three to six months of combined HRT is expected. If unscheduled bleeding continues beyond six months, or if it is heavy, your clinician should first rule out structural causes (polyps, fibroids, endometrial pathology) with ultrasound or biopsy. ACOG Practice Bulletin No. 128 on diagnosis of abnormal uterine bleeding provides the evaluation framework. If pathology is excluded and the bleeding is driven by inadequate endometrial suppression, the LNG-IUD's direct local action may be more effective than oral progesterone at controlling the lining.

Confirmed Endometrial Hyperplasia

If a biopsy returns with simple hyperplasia without atypia while you are on Prometrium, that is a clear signal the oral route is not providing sufficient endometrial protection for you. The LNG-IUD has strong evidence for treating simple endometrial hyperplasia. A 2021 systematic review in the American Journal of Obstetrics and Gynecology found regression rates of 91-96% for non-atypical hyperplasia treated with the LNG-IUS, compared to approximately 80% for oral progestogens.

When the LNG-IUD "Fails": What That Looks Like and What to Do

IUD Expulsion

Expulsion rates for Mirena are approximately 2-10% in the first year, varying by uterine size, cavity distortion, and whether you had a recent delivery. If your IUD expels, you lose endometrial protection and contraception simultaneously. Your clinician can attempt reinsertion, or you can switch to oral Prometrium. Partial expulsion is less obvious and may present as renewed bleeding or a string that feels longer than usual.

Persistent Irregular Bleeding

Irregular spotting in the first three to six months after Mirena insertion is expected and generally resolves as the endometrium thins. Bleeding that continues heavily beyond six months, or that restarts after a period of amenorrhea, should prompt an ultrasound to check device position and endometrial thickness. If position is confirmed normal and bleeding persists, some clinicians adjust the systemic estrogen dose downward rather than removing the IUD.

Systemic Levonorgestrel Sensitivity

A small proportion of women notice androgenic effects from levonorgestrel even at the low blood levels from the IUD: acne, oily skin, or mild mood changes. Because the molecule is synthetic and androgenic, these effects are biologically plausible even when rare. Switching to Prometrium eliminates the androgenic component entirely.

A Decision Framework for Switching

Use this four-question screen before deciding to switch:

1. Is the "failure" a side effect or a protection failure? Side effects drive a switch to the IUD; protection failure (hyperplasia, persistent heavy bleeding) may support the IUD or require a different approach entirely.
2. Do you still need contraception? If you are in perimenopause and have not had 12 consecutive months without a period, you still need contraception. Prometrium provides none. The IUD does.
3. Is there a structural uterine factor? Fibroids or a significantly distorted cavity raise the IUD expulsion risk. Oral Prometrium has no such mechanical limitation.
4. What are your bleeding goals? If amenorrhea is your priority, the LNG-IUD eventually achieves that in most women. Sequential Prometrium produces a monthly withdrawal bleed by design.

Life-Stage Considerations: Perimenopause vs Post-Menopause

Perimenopause

Your ovaries are still functioning unpredictably. Estrogen fluctuates, cycles are irregular, and you may have anovulatory cycles that produce progesterone deficiency even without full menopause. You still need contraception until you have been amenorrheic for 12 consecutive months (if over 50) or 24 consecutive months (if under 50), per FSRH guidance.

The Mirena IUD is particularly well-suited to this stage. It suppresses the endometrium, reduces heavy perimenopausal bleeding, and provides highly effective contraception simultaneously. One device does three jobs. Prometrium can be used in perimenopause but provides no contraception, and the cyclical dosing schedule can feel complicated when your natural cycle is already erratic.

ACOG Practice Bulletin No. 141 notes that perimenopausal women with heavy bleeding are candidates for LNG-IUS as a first-line intervention.

Post-Menopause

After 12 consecutive months of amenorrhea, contraception is no longer a factor. The choice simplifies to: which progestogen gives you the best balance of endometrial protection and tolerability?

For women who manage continuous combined HRT well, Prometrium 100 mg nightly is straightforward and evidence-backed. For women who develop side effects or have a history of progesterone sensitivity, the IUD remains an option in post-menopause, though insertion can be more technically challenging after the cervix has atrophied. Cervical softening with misoprostol or topical estrogen pre-insertion is sometimes used; your clinician will assess this.

Women with PCOS

If you have polycystic ovary syndrome and are entering perimenopause or menopause, your endometrial risk profile may already be elevated from years of anovulation and unopposed estrogen. ACOG Practice Bulletin No. 194 on PCOS highlights endometrial hyperplasia as a long-term risk requiring progestogen protection. Either Prometrium or the LNG-IUD provides that protection, but the IUD's direct endometrial action may offer more consistent local suppression in women whose endometrium has been chronically unstimulated-then-overstimulated.

Pregnancy and Lactation Safety

If you are pregnant, neither Prometrium as HRT nor a levonorgestrel IUD should be in place. This section is included because perimenopause and early post-menopause can overlap with situations where pregnancy, though unlikely, is still possible.

Prometrium in Pregnancy

Prometrium (micronized progesterone) is used therapeutically in early pregnancy to support the luteal phase in IVF and in women with recurrent pregnancy loss. In that context, it is considered relatively safe in the first trimester. However, Prometrium as formulated for HRT (the 100 mg or 200 mg oral capsule, which contains peanut oil) is not the same as vaginally administered progesterone used in reproductive medicine. Women with peanut allergy should not use Prometrium capsules at any stage.

If you become pregnant while on Prometrium as HRT, stop the estrogen and contact your provider immediately. The progesterone component is less immediately harmful, but HRT-dose estrogen is not indicated in pregnancy.

Levonorgestrel IUD in Pregnancy

If the IUD is in situ and pregnancy occurs (rare, given >99% efficacy), the device should be removed as early as possible. Leaving a Mirena or Kyleena in place during pregnancy carries risks of miscarriage, preterm birth, and infection. The FDA prescribing information for Mirena explicitly states that if pregnancy occurs with the IUD in place and the patient wants to continue the pregnancy, the IUD should be removed if the strings are visible.

Lactation

Prometrium in HRT doses is not appropriate postpartum. Systemic estrogen used in HRT suppresses lactation and is contraindicated while breastfeeding. Progesterone alone in low doses (as in progestogen-only pills) does not significantly suppress milk supply, but the HRT regimen as a whole (estrogen plus progesterone) is not appropriate in the breastfeeding period.

The levonorgestrel IUD releases no estrogen and has minimal systemic levonorgestrel levels; it is considered compatible with breastfeeding for contraceptive purposes. However, postpartum women using a Mirena for contraception are not typically also on systemic estrogen HRT, so this scenario rarely applies in the HRT context.

Contraception Requirements

If you are in perimenopause and still cycling (even irregularly), you are not infertile. Prometrium provides zero contraceptive protection. If you are using Prometrium as the progestogen in your HRT regimen and you need contraception, you must use a separate reliable contraceptive method. The LNG-IUD covers both needs simultaneously, which is one of its most clinically practical advantages in the perimenopausal years.

Who This Approach Is Right For and Who Should Think Twice

Strong candidates for Prometrium

• Post-menopausal women who tolerate oral progesterone well and prefer a simple pill-based regimen
• Women for whom an IUD insertion procedure is not feasible (significant cervical stenosis, uterine anomaly)
• Women who want to avoid any synthetic hormone and prefer a bioidentical molecule
• Women whose HRT regimen is already stable and well-tolerated

Strong candidates for the LNG-IUD

• Perimenopausal women who need contraception alongside endometrial protection
• Women who have tried Prometrium and experienced significant sedation, mood changes, or breast tenderness
• Women with a history of heavy menstrual bleeding or fibroids causing heavy periods
• Women with confirmed simple endometrial hyperplasia needing both treatment and ongoing protection

Women who need additional evaluation before either

• Women with unexplained uterine bleeding (requires structural workup before starting or continuing HRT)
• Women with known atypical endometrial hyperplasia or endometrial cancer (these require oncology input, not a progestogen switch alone)
• Women with a severely distorted uterine cavity (large fibroids, mullerian anomaly) where IUD insertion is high-risk and oral progesterone adequacy needs monitoring with periodic biopsy

Monitoring: How You Know Either Option Is Working

"Working" means your endometrium is not hyperplastic. Neither Prometrium nor the IUD comes with a visible dashboard. Monitoring relies on symptom surveillance and, when indicated, imaging or biopsy.

• Any new or changed bleeding pattern after six months of stable HRT should be investigated. Do not assume it is benign.
• Transvaginal ultrasound to measure endometrial thickness is the first-line tool. An endometrial stripe above 4 mm in a post-menopausal woman on HRT warrants further evaluation.
• Endometrial biopsy is indicated for persistent bleeding regardless of ultrasound findings, per ACOG guidance.
• Women using the LNG-IUD for HRT endometrial protection should have a string check at their annual visit to confirm device position.

If you are on Prometrium and your clinician recommends a biopsy, do not delay it. A normal biopsy is the evidence that your regimen is working.